Balyo SA (EPA:BALYO) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Balyo SA (EPA:BALYO) shareholders are probably feeling a little disappointed, since its shares fell 3.4% to €2.42 in the week after its latest third-quarter results. Revenues were €6.4m, and Balyo came in a solid 15% ahead of expectations. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

Check out our latest analysis for Balyo

earnings-and-revenue-growth
ENXTPA:BALYO Earnings and Revenue Growth March 21st 2021

Taking into account the latest results, the most recent consensus for Balyo from three analysts is for revenues of €36.6m in 2021 which, if met, would be a major 69% increase on its sales over the past 12 months. Earnings are expected to improve, with Balyo forecast to report a statutory profit of €0.042 per share. Before this earnings announcement, the analysts had been modelling revenues of €24.7m and losses of €0.16 per share in 2021. So we can see that the latest results have sparked a pretty clear upgrade to expectations, with higher revenues expected to lead to profit sooner than previously forecast.

With these upgrades, we're not surprised to see that the analysts have lifted their price target 38% to €2.40per share. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Balyo, with the most bullish analyst valuing it at €2.90 and the most bearish at €1.50 per share. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's clear from the latest estimates that Balyo's rate of growth is expected to accelerate meaningfully, with the forecast 52% annualised revenue growth to the end of 2021 noticeably faster than its historical growth of 22% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 23% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Balyo is expected to grow much faster than its industry.

Advertisement

The Bottom Line

The most important thing to take away is that the analysts now expect Balyo to become profitable next year, compared to previous expectations that it would report a loss. Happily, they also upgraded their revenue estimates, and are forecasting revenues to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for Balyo going out to 2023, and you can see them free on our platform here.

That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Balyo , and understanding these should be part of your investment process.

If you decide to trade Balyo, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted


Valuation is complex, but we're here to simplify it.

Discover if Balyo might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020


Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

About ENXTPA:BALYO

Balyo

Designs, develops, and markets material handling robots worldwide.

Adequate balance sheet with minimal risk.

Similar Companies

Advertisement

Weekly Picks

ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Looking to be second time lucky with a game-changing new product

Fair Value:US$21.5360.5% undervalued
135 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative
DE
Degen_GCR
P logo
Degen_GCR on Everpure ·

Second order memory play likely to double in a year

Fair Value:US$18053.1% undervalued
17 users have followed this narrative
1 users have commented on this narrative
11 users have liked this narrative
DO
Double_Bubbler
LUNR logo
Double_Bubbler on Intuitive Machines ·

Intuitive Machines: To The Moon and Beyond!

Fair Value:US$42.324.1% undervalued
8 users have followed this narrative
0 users have commented on this narrative
4 users have liked this narrative
YI
APP logo
yiannisz on AppLovin ·

AppLovin’s AI Engine Is Printing Profit

Fair Value:US$989.2454.2% undervalued
30 users have followed this narrative
2 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

KA
kapirey
UNCY logo
kapirey on Unicycive Therapeutics ·

Unicycive Therapeutics is a late-stage clinical biotech transitioning toward commercialization

Fair Value:US$9.177.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KA
kapirey
1364 logo
kapirey on Guming Holdings ·

A scaled, high-growth, franchise-driven beverage leader with strong penetration in China

Fair Value:HK$47.5650.7% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
HE
HedgeY
IONQ logo
HedgeY on IonQ ·

The Best-Funded Quantum Platform and Still a Stock Priced for Perfection

Fair Value:US$4815.1% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

GO
QS logo
GoldenSands on QuantumScape ·

QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Fair Value:US$8589.8% undervalued
108 users have followed this narrative
2 users have commented on this narrative
31 users have liked this narrative
KI
NVDA logo
Kingman1152 on NVIDIA ·

NVIDIA will see a profit margin surge of 55% in the next 5 years

Fair Value:US$305.226.0% undervalued
70 users have followed this narrative
2 users have commented on this narrative
24 users have liked this narrative
TR
tripledub
META logo
tripledub on Meta Platforms ·

The $135 Billion Bet That Should Make Every Shareholder Nervous

Fair Value:US$74016.7% undervalued
35 users have followed this narrative
3 users have commented on this narrative
33 users have liked this narrative